Online citations, reference lists, and bibliographies.
← Back to Search

Oral Cyclosporine A - The Current Picture Of Its Liposomal And Other Delivery Systems

A. Czogalla
Published 2008 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
The discovery of cyclosporine A was a milestone in organ transplantation and the treatment of autoimmune diseases. However, developing an efficient oral delivery system for this drug is complicated by its poor biopharmaceutical characteristics (low solubility and permeability) and the need to carefully monitor its levels in the blood. Current research is exploring various approaches, including those based on emulsions, microspheres, nanoparticles, and liposomes. Although progress has been made, none of the formulations is flawless. This review is a brief description of the main pharmaceutical systems and devices that have been described for the oral delivery of cyclosporine A in the context of the physicochemical properties of the drug and the character of its interactions with lipid membranes.
This paper references
liposomes and intralipid
S. Venkataram (1990)
10.1016/J.FARMAC.2005.08.008
Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers.
P. Sharma (2005)
10.5860/choice.44-5373
The Merck index : an encyclopedia of chemicals, drugs, and biologicals
S. Budavari (1983)
a stability study
F. Lallemand (2005)
10.1080/03639040500388573
Enhancing the Bioavailability of Cyclosporine A Using Solid Dispersion Containing Polyoxyethylene (40) Stearate
C. Liu (2006)
10.1111/J.1399-3011.2003.00111.X
Cyclosporin A prodrugs: design, synthesis and biophysical properties.
A. Hamel (2004)
Interactions of cyclosporine and some derivatives with model membranes: binding and ion permeability changes.
A. Fahr (1994)
10.1002/JPS.10444
Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal.
D. Lechuga-Ballesteros (2003)
10.1016/S0378-5173(02)00490-8
Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion in rats.
S. Kim (2002)
10.1016/0378-5173(94)00243-X
Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporin
A. Al-Angary (1995)
Binding and ion permeability changes
A. Fahr (1994)
10.1016/S0378-5173(98)00066-0
Oral administration of liposomes containing cyclosporine: a pharmacokinetic study
M. Al-Meshal (1998)
10.1166/JNN.2006.403
Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A.
N. Shah (2006)
Cyclosporine-loaded Unauthenticated Download Date | 4 152 polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats
M C Varela (2001)
design, synthesis and biophysical properties
A. R. Hamel (2004)
10.1016/S0168-3659(02)00239-0
Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer.
W. Lee (2002)
10.1002/HLCA.19760590509
Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A.
T. Petcher (1976)
10.1002/JPS.20057
Cyclosporin nanoparticulate lipospheres for oral administration.
Tania Bekerman (2004)
10.1002/JPS.10071
Interactions of cyclosporines with lipid membranes as studied by solid-state nuclear magnetic resonance spectroscopy and high-sensitivity titration calorimetry.
U. Schote (2002)
Biophysical characterisation of liposomal delivery systems for lipophilic drugs: cyclosporin A as an example
A. Fahr (1999)
consequences for drug delivery
A. Fahr (2005)
10.1023/A:1018936806278
Stability of Liposomes in Vitro and Their Uptake by Rat Peyer's Patches Following Oral Administration
Y. Aramaki (2004)
Cyclosporine-loaded Unauthenticated Download Date | 4/12/17
M. C. Varela (2009)
10.1097/00007890-199403270-00027
THE INCREASED EFFICACY AND DECREASED NEPHROTOXICITY OF A CYCLOSPORINE LIPOSOME1,2
C. Freise (1994)
10.1126/SCIENCE.1566062
A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex.
D. Altschuh (1992)
Solubilization of Cyclosporin A. AAPS Pharm. Sci. Tech
Y Ran (2001)
10.1016/0009-9236(95)90168-X
Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine
C. Wu (1995)
10.1016/J.TRANSPROCEED.2004.01.091
Therapeutic drug monitoring of cyclosporine: 20 years of progress.
B. Kahan (2004)
10.1021/JM00076A002
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
N. El Tayar (1993)
effect of cholesterol
T. Soderlund (1999)
10.1002/JPS.2600790307
Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid.
S. Venkataram (1990)
10.1016/S0378-5173(02)00461-1
Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A.
M. H. El-Shabouri (2002)
10.1016/S0378-5173(02)00339-3
Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension.
R. B. Bravo González (2002)
Eds) The Merck Index – an encyclopedia of chemicals, drugs, and biologicals, 14 edition, Merck & Co., Inc
M. J. O’Neal (2006)
10.1023/A:1016062224568
Estimation of the Increase in Solubility of Drugs as a Function of Bile Salt Concentration
S. D. Mithani (2004)
Studies with cyclosporine
C. Y. Wu (1995)
10.1002/HLCA.19840670220
Synthesis of cyclosporine. Total syntheses of ‘cyclosporin A’ and ‘cyclosporin H’, two fungal metabolites isolated from the species Tolypocladium inflatum GAMS
R. Wenger (1984)
10.1002/JPS.10590
Incorporation of lipophilic drugs in sugar glasses by lyophilization using a mixture of water and tertiary butyl alcohol as solvent.
D. V. van Drooge (2004)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1097/00007890-199511150-00021
LIPOSOMAL CYCLOSPORINE: CHARACTERIZATION OF DRUG INCORPORATION AND INTERBILAYER EXCHANGE
C. Ouyang (1995)
Cyclosporin A as an example
A. Fahr (1999)
10.1016/S0928-0987(02)00048-9
Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion and microsphere formulations in rabbits.
S. Kim (2002)
10.1016/S0939-6411(00)00143-0
Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers.
R. Gref (2001)
10.1111/j.2042-7158.1991.tb06688.x
Unusual solubility behaviour of cyclosporin A in aqueous media
G. Ismailos (1991)
10.1021/JO00056A013
Total synthesis of 1233A
P. Wovkulich (1993)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1007/BF03190040
Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4
P. Kelly (2010)
Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophore side-effect.
G. Thiel (1986)
10.1021/BM060130L
Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds.
W. P. Cheng (2006)
10.1111/j.1432-2277.2005.00078.x
Generic cyclosporine formulations: more open questions than answers
D. Cattaneo (2005)
Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporine
K. Kajitani (2008)
10.1159/000044912
Impaired Antioxidant Defense System in the Kidney Tissues from Rabbits Treated with Cyclosporine
İ. Durak (1998)
10.1016/J.TRANSPROCEED.2004.01.022
Experience with cyclosporine.
A. Langone (2004)
10.1016/0005-2736(90)90003-7
Interaction of cyclosporin A with dipalmitoylphosphatidylcholine.
T. Wiedmann (1990)
10.3109/02652049109069554
Liposomes as cyclosporin A carriers: the influence of ordering of hydrocarbon chains of phosphatidylglycerol liposomes on the association with and topography of cyclosporin A.
L. Stuhne-Sekalec (1991)
10.1016/S0378-5173(00)00361-6
Studies on the cyclosporin A loaded stearic acid nanoparticles.
Q. Zhang (2000)
Effect of temperature on molecular structure of cyclosporin A.
H. Hasumi (1994)
10.1016/J.IJPHARM.2005.06.002
Novel gels and their dispersions--oral drug delivery systems for ciclosporin.
S. Murdan (2005)
10.1002/prot.21855
Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporin A at 0.96‐Å resolution
K. Kajitani (2008)
10.1002/JPS.2600830336
Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.
J. Kovarik (1994)
Cyclosporine-loaded Unauthenticated Download Date | 4/20/17
M. C. Varela (2009)
Enhancement of dissolution of cyclosporine A using solid dispersions with polyoxyethylene (40) stearate.
C. Liu (2006)
10.1002/9783527620999.CH12G
Cyclosporins: Recent Developments in Biosynthesis, Pharmacology and Biology, and Clinical Applications
J. Kallen (2001)
10.1023/A:1016220211925
Liposomal Formulations of Cyclosporin A: Influence of Lipid Type and Dose on Pharmacokinetics
A. Fahr (2004)
10.1111/J.1365-2125.1986.TB05200.X
The effect of vehicle on the oral absorption of cyclosporin.
A. Johnston. (1986)
10.1016/S0378-5173(01)00621-4
Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres.
E. Lee (2001)
10.1016/S0169-409X(97)00043-4
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery.
Hébert (1997)
a cremophor sideeffect
G. Thiel (1986)
Cyclosporine nephrotoxicity. Transplant
A. Busauschina (2004)
evidence from partition coefficients and molecular dynamics simulations
N. El Tayar (1993)
10.1016/J.JCONREL.2007.02.004
PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
J. L. Italia (2007)
10.1124/MOL.55.1.32
Interactions of cyclosporin A with phospholipid membranes: effect of cholesterol.
T. Söderlund (1999)
10.1007/BF00180747
Progress towards a molecular understanding of cyclosporin A-mediated immunosuppression
A. Schumacher (1992)
10.1016/J.IJPHARM.2007.08.050
Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability.
J. Woo (2007)
10.1016/S0079-6468(08)70303-5
Biosynthesis and mechanism of action of cyclosporins.
A. Lawen (1996)
10.1016/0009-9120(91)90084-R
Pharmacology and pharmacokinetics of cyclosporine.
D. Freeman (1991)
10.2165/00003495-200161130-00006
Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
C. Dunn (2001)
Druglipid physicochemical interactions and characterization of drug incorporation
R. H. Mueller (2008)
An updated review of the pharmacokinetic properties, clinical efficiacy and tolerability of a microemulsion-based formulation (Neoral®) in organ transplantation
C J Dunn (2001)
10.1111/j.1476-5381.1996.tb15612.x
Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation
G. Fricker (1996)
10.1016/J.DRUDIS.2006.07.015
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
J. L. Italia (2006)
10.1016/J.EJPS.2005.05.012
Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.
A. Fahr (2005)
10.1208/pt020102
Solubilization of cyclosporin A
Y. Ran (2008)
LETT . 152 polycaprolactone nanoparticles : immunosuppression and nephrotoxicity in rats
J. Dai (2001)
Contributions of hepatic and intestinal metabolism and Pglycoprotein to cyclosporine and tacrolimus oral drug
M. F. Hebert (1997)
Total synthesis of “cyclosporin A” and “cyclosporin H”, two fungal metabolites isolated from species Tolypocladium inflatum Gams
R. M. Wenger (1984)
10.7326/0003-4819-99-6-851
Cyclosporine nephrotoxicity.
W. Bennett (1983)
10.1016/J.IJPHARM.2006.05.021
Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid.
Xue-qing Wang (2006)
10.1016/S0928-0987(00)00198-6
Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats.
M. C. Varela (2001)
10.1016/J.CHEMPHYSLIP.2004.04.002
Effects of cyclosporin A on model lipid membranes.
M. Lambros (2004)
10.1007/s11095-004-1188-0
Engineering Polysaccharide-Based Polymeric Micelles to Enhance Permeability of Cyclosporin A Across Caco-2 Cells
M. Francis (2004)
10.1016/J.IJPHARM.2004.05.006
pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A.
Jundong Dai (2004)
10.1203/00006450-199704001-00009
State of the Art
M. Völter (1997)
10.1016/J.EJPB.2007.07.006
Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation.
R. Mueller (2008)
a pharmacokinetic study
M. A. Al-Meshal (1998)
immunosuppression and nephrotoxicity in rats
M. C. Varela (2001)
10.1016/0378-5173(90)90226-T
Crosslinked starch as a disintegrating agent
N. Visavarungroj (1990)
10.1016/J.INTIMP.2005.03.021
Protective role of melatonin in cyclosporine A-induced oxidative stress in rat liver.
R. Rezzani (2005)
10.1002/cbic.200500146
Structure Refinement of Cyclosporin A in Chloroform by Using RDCs Measured in a Stretched PDMS‐Gel
Jochen Klages (2005)
10.1016/J.JCONREL.2004.03.003
Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration.
Xue-qing Wang (2004)
10.1021/BI00240A029
The NMR structure of cyclosporin A bound to cyclophilin in aqueous solution.
C. Weber (1991)
10.1016/S0378-5173(99)00177-5
A polycaprolactone nanoparticle formulation of cyclosporin-A improves the prediction of area under the curve using a limited sampling strategy.
J. Molpeceres (1999)
10.2165/00003495-199550050-00009
Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
S. Noble (1995)
10.1016/S0149-2918(03)80161-3
A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporin A
S. Pollard (2003)
more open questions than answers
D. Cattaneo (2005)
10.1016/S0378-5173(00)00680-3
Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral.
J. Guo (2001)
10.1248/BPB.22.66
Enhanced absorption of cyclosporin A by complexation with dimethyl-beta-cyclodextrin in bile duct-cannulated and -noncannulated rats.
K. Miyake (1999)
10.1016/J.EJPS.2005.05.003
A water-soluble prodrug of cyclosporine A for ocular application: a stability study.
F. Lallemand (2005)
[20 YEARS OF PROGRESS].
L. Vaskov (1964)



This paper is referenced by
10.1016/j.addr.2020.06.016
Noninvasive transdermal delivery of liposomes by weak electric current.
Mahadi Hasan (2020)
10.1208/s12248-018-0231-8
The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration
A. Kourentas (2018)
10.1016/j.jconrel.2020.10.044
Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles.
K. Park (2020)
10.1007/s00232-015-9814-9
Cyclosporin A in Membrane Lipids Environment: Implications for Antimalarial Activity of the Drug—The Langmuir Monolayer Studies
P. Dynarowicz-Łątka (2015)
10.3341/kjo.2018.0116
Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
C. Park (2019)
10.1016/j.ejpb.2017.03.006
Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts
F. Lallemand (2017)
10.1007/978-1-4614-5034-4_13
The Skin Immune System
A. Nasir (2013)
10.1016/j.jconrel.2010.11.009
Ophthalmic delivery of cyclosporine A by punctal plugs.
C. Gupta (2011)
10.1007/s11095-010-0130-x
Phospholipids and Lipid-Based Formulations in Oral Drug Delivery
G. Fricker (2010)
10.1021/acs.molpharmaceut.7b00994
Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening
S. Bhatnagar (2018)
10.1016/j.ijpharm.2010.08.007
Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.
S. Onoue (2010)
10.1016/j.colsurfb.2018.03.031
Cyclosporin A distribution in cholesterol-sphingomyelin artificial membranes modeled as Langmuir monolayers.
Anita Wnętrzak (2018)
10.1186/s12886-019-1136-8
Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial
C. H. Park (2019)
10.2147/OPTH.S244287
Effectiveness of Subconjunctival Cyclosporine in Treatment of Acute Allergic Conjunctivitis in a Rat-Model
A. Awara (2020)
10.1016/j.bmc.2014.11.034
Improving the passive permeability of macrocyclic peptides: Balancing permeability with other physicochemical properties.
P. Thansandote (2015)
10.1016/j.ejpb.2010.09.012
Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study.
K. Mondon (2011)
10.1021/la201040c
The potent antimalarial peptide cyclosporin A induces the aggregation and permeabilization of sphingomyelin-rich membranes.
Slim Azouzi (2011)
10.1002/9781444355628.CH15
Cyclosporine: Molecular Action to Clinical Therapeutics
B. Strijack (2012)
NMR and Gas Sorption Studies of Structure-Transport Relationships in Porous Media
Elenica Shiko (2013)
Novel micellar systems for the formulation of poorly water soluble drugs : biocompatibility aspects and pharmaceutical applications
K. Mondon (2010)
10.1016/j.ijpharm.2013.05.014
Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs.
X. Zhang (2013)
10.1016/j.jconrel.2011.05.024
Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs.
S. Biagiotti (2011)
10.1208/s12248-011-9259-8
The Immunosuppressive Activity of Polymeric Micellar Formulation of Cyclosporine A: In Vitro and In Vivo Studies
S. Hamdy (2011)
10.1007/s10973-019-08197-6
Temperature-dependent interactions in the chitosan/cyclosporine A system at liquid–air interface
M. Jurak (2019)
10.1111/bph.12722
Immunosuppressive and anti‐inflammatory properties of engineered nanomaterials
A. Ilinskaya (2014)
Engineering of polymeric nanoparticles based on structure-activity relationships (SARs) for oral drug delivery
U. Odunze (2018)
10.1021/ACSOMEGA.9B00603
Solubility Studies of Cyclosporine Using Ionic Liquids
Paula Berton (2019)
10.3390/ijms151018040
Novel Formulations for Antimicrobial Peptides
A. M. Carmona-Ribeiro (2014)
Devices and mechanisms for ophthalmic drug delivery
Chhavi Gupta (2010)
10.1016/j.ejps.2016.09.015
Self‐micellizing solid dispersion of cyclosporine A for pulmonary delivery: Physicochemical, pharmacokinetic and safety assessments
H. Suzuki (2017)
10.2147/IJN.S19259
Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt
Peipei Guan (2011)
10.1016/j.ejpb.2009.06.001
Lipid--an emerging platform for oral delivery of drugs with poor bioavailability.
S. Chakraborty (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar